Rufinamide as add-on therapy in children with epileptic encephalopathies other than Lennox–Gastaut syndrome: A study of 34 patients | ||
| dc.conicet.organizacion | Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan" | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas | |
| dc.conicet.organizacion | Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan" | |
| dc.conicet.organizacion | Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan" | |
| dc.conicet.organizacion | Hospital Materno Infantil de Salta | |
| dc.conicet.organizacion | Hospital de Niños Víctor J Vilela | |
| dc.conicet.organizacion | Clínica San Lucas | |
| dc.conicet.organizacion | Clínica San Lucas | |
| dc.contributor.author | Caraballo, Roberto Horacio | |
| dc.contributor.author | Pociecha, Juan | |
| dc.contributor.author | Reyes, Gabriela | |
| dc.contributor.author | Espeche, Alberto Antonio | |
| dc.contributor.author | Galichio, Santiago | |
| dc.contributor.author | Fasulo, Lorena | |
| dc.contributor.author | Semprino, Marcos | |
| dc.date.issued | 2020-07 | |
| dc.description.abstract | Objective: Here, we present a multicenter series of patients with developmental and epileptic encephalopathies (DEE) and related electroclinical patterns (REP) other than Lennox–Gastaut syndrome (LGS) who were treated with rufinamide as add-on therapy. Methods: Medical records of 34 patients with DEE and REP other than LGS treated with add-on rufinamide seen at four pediatric neurology centers in Argentina between May 2014 and March 2019 were retrospectively analyzed. Results: We evaluated 34 patients (18 males, 16 females), aged between 2 and 15 years with a mean and median age of 6 and 8 years, respectively. The children had different types of childhood-onset refractory DEE and REP other than LGS and were treated with rufinamide for a mean period of 20 months (range, 12–60 months). Twenty-two of 34 patients (64.5%) who received rufinamide as add-on therapy had a greater than 50% decrease in seizures, and two patients (5.8%) became seizure-free. Four patients (11.7%) had a 25–50% seizure reduction, while seizure frequency remained unchanged in four others (11.7%) and increased in two patients (5.8%). The final mean dosage of rufinamide was 31.5 ± 15.5 mg/kg per day (range, 19–75.4 mg/kg) if combined with valproic acid and of 35.4 ± 11.5 mg/kg per day (range, 8–60.5 mg/kg) without valproic acid. Adverse effects were recorded in nine patients (26.4%). A seizure increase was reported in two of 24 patients (7.3%). Conclusion: Rufinamide may be used as a treatment option in DEE and REP other than LGS. | es |
| dc.description.fil | Fil: Caraballo, Roberto Horacio. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina | |
| dc.description.fil | Fil: Pociecha, Juan. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina | |
| dc.description.fil | Fil: Reyes, Gabriela. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina | |
| dc.description.fil | Fil: Espeche, Alberto Antonio. Hospital Materno Infantil de Salta; Argentina | |
| dc.description.fil | Fil: Galichio, Santiago. Hospital de Niños Víctor J Vilela; Argentina | |
| dc.description.fil | Fil: Fasulo, Lorena. Clínica San Lucas; Argentina | |
| dc.description.fil | Fil: Semprino, Marcos. Clínica San Lucas; Argentina | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Caraballo, Roberto Horacio; Pociecha, Juan; Reyes, Gabriela; Espeche, Alberto Antonio; Galichio, Santiago; et al.; Rufinamide as add-on therapy in children with epileptic encephalopathies other than Lennox–Gastaut syndrome: A study of 34 patients; Academic Press Inc Elsevier Science; Epilepsy & Behavior (print); 108; 107074; 7-2020; 1-6 | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.issn | 1525-5050 | es |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/170200 | |
| dc.journal.number | 107074 | es |
| dc.journal.pagination | 1-6 | es |
| dc.journal.pais | Estados Unidos | es |
| dc.journal.title | Epilepsy & Behavior (print) | es |
| dc.journal.volume | 108 | es |
| dc.language.iso | eng | es |
| dc.publisher | Academic Press Inc Elsevier Science | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.yebeh.2020.107074 | |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S1525505020302535 | |
| dc.rights | info:eu-repo/semantics/restrictedAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | * |
| dc.subject | EPILEPTIC ENCEPHALOPATHIES | es |
| dc.subject | FOCAL AND GENERALIZED | es |
| dc.subject | REFRACTORY | es |
| dc.subject | RUFINAMIDE | es |
| dc.subject | SEIZURES | es |
| dc.subject.classification | Neurología Clínica | es |
| dc.subject.classification | Medicina Clínica | es |
| dc.subject.classification | CIENCIAS MÉDICAS Y DE LA SALUD | es |
| dc.title | Rufinamide as add-on therapy in children with epileptic encephalopathies other than Lennox–Gastaut syndrome: A study of 34 patients | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.66d5c223-904d-4d54-a8bb-fb3e134b3227_B.pdf
- Tamaño:
- 1.1 MB
- Formato:
- Adobe Portable Document Format